anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
Chimerix · pitchdeck

Chimerix | Investor Presentation Deck | 41 slides

41 pages · 4 arc beats · 2 loops

Pitchdeck Download JSON
Unlock

Chimerix | Investor Presentation Deck | 41 slides

Chimerix · 2023-05
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON
Narrative range 11 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem Statement 1 slides 100% 1/1 slides 100% 1/1 slides · 6 hits
— 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides Traction 8 slides 100% 8/8 slides 100% 8/8 slides · 40 hits
— 0/8 slides
75% 6/8 slides · 8 hits 12.5% 1/8 slides 100% 8/8 slides 100% 8/8 slides Solution 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits
— 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides
— 0/1 slides
Market Sizing 1 slides 100% 1/1 slides 100% 1/1 slides · 3 hits
— 0/1 slides
100% 1/1 slides · 2 hits
— 0/1 slides
100% 1/1 slides
— 0/1 slides

Slide inventory

41
every slide · same image gating as the playbook
01
Slide 1
front_matter
Open slide detail
02
other
Open slide detail
03
summarize
Open slide detail
04
The slide uses a Gantt-style chart to map drug candidates against development phases.plan_implementation
Open slide detail
05
transition
Open slide detail
06
Includes Kaplan-Meier survival curves and a comparative table of clinical outcomes.frame_problem
Open slide detailBeat · Problem StatementLoop · Cost Of Inaction
07
Data presented includes ORR, DOR, time to response, disease control rate, PFS, and overall survival metrics.show_traction
Open slide detailBeat · TractionLoop · Cost Of Inaction
08
The slide details specific inclusion/exclusion criteria including age, mutation status, disease progression, prior therapy, and washout periods.present_framework
Open slide detailBeat · TractionLoop · Cost Of Inaction
09
The slide highlights clinical response rates (20-26%) and disease control rates (40-42%) using rigorous BICR methodology.show_traction
Open slide detailBeat · TractionLoop · Cost Of Inaction
10
The chart is a waterfall plot (often called a swimmer plot or spider plot in oncology, but specifically a waterfall plot here).show_traction
Open slide detailBeat · TractionLoop · Cost Of Inaction
11
The slide uses a waterfall plot to visualize tumor shrinkage (Best % Change in SPD) across different patient performance status cohorts.analyze_data
Open slide detailBeat · TractionLoop · Cost Of Inaction
12
The chart is a 'spider plot' or 'swimmer plot' variant showing % change in tumor size over time.show_traction
Open slide detailBeat · TractionLoop · Cost Of Inaction
13
Presents safety data tables for two distinct patient populations.analyze_data
Open slide detailBeat · TractionLoop · Cost Of Inaction
14
Data table comparing All patients vs RANO HGG Responders vs RANO HGG and/or LGG Responders across survival and clinical metrics.show_traction
Open slide detailBeat · TractionLoop · Cost Of Inaction
15
The table uses a color-coded heatmap (green/pink) to indicate positive vs negative characteristics of trial design and outcomes.compare_peers
Open slide detail
16
transition
Open slide detail
17
The slide uses a process flow diagram to illustrate the clinical trial structure.plan_implementation
Open slide detail
18
summarize
Open slide detail
19
The slide details specific statistical success thresholds for different trial endpoints.plan_implementation
Open slide detail
20
The chart shows a dose-response curve where longer incubation times (48+ hours) shift the curve to the left compared to 24 hours, indicating higher potency/effipresent_solution
Open slide detailBeat · Solution
21
transition
Open slide detail
22
size_opportunity
Open slide detailBeat · Market Sizing
23
The slide lists specific regulatory milestones achieved for glioma treatments.establish_context
Open slide detail
24
Clinical trial data (NCT03034200) presented at ASCO 2021.show_traction
Open slide detail
25
transition
Open slide detail
26
Includes a BioRender diagram illustrating the molecular pathway.present_solution
Open slide detail
27
Includes PET scan imagery and comparative bar/dot plots.present_solution
Open slide detail
28
Includes a schematic of the mutation, a bar chart of H3K27me3 levels, a Kaplan-Meier survival curve, and a dot plot showing treatment effect.present_solution
Open slide detail
29
transition
Open slide detail
30
Includes molecular structure of ONC206 and protein structures for DRD2 and ClpP.present_solution
Open slide detail
31
The slide uses a human body diagram to categorize tumor types and presents preclinical data for each.show_traction
Open slide detail
32
The slide uses two charts: a dose-response curve showing increased efficacy with longer incubation times, and a PK model showing plasma concentration over time present_solution
Open slide detail
33
The slide highlights early clinical efficacy data from a dose escalation trial.show_traction
Open slide detail
34
Includes a visual representation of survival rates (1 out of 20).size_opportunity
Open slide detail
35
transition
Open slide detail
36
The slide includes a visual comparison of tumor burden in mice models (Vehicle vs ONC201 vs ONC212).present_solution
Open slide detail
37
Includes a dot plot showing significant reduction in viral lung titer across various treatment initiation times compared to vehicle.present_solution
Open slide detail
38
transition
Open slide detail
39
analyze_data
Open slide detail
40
The slide uses a process-like flow to connect financial strength to clinical milestones.argue_timing
Open slide detailLoop · Why Now
41
front_matter
Open slide detail